Intercellular adhesion molecule-1 (ICAM1) acts as ligand for b2-integrin molecules and mediates leucocyte trafficking to the site of inflammation. Intercellular adhesion molecule-1-deficient mice show impaired lymphocyte recruitment to the lung, less airway hyper-responsiveness and less lung inflammation than healthy controls. Thus, the aim of the study was to test common ICAM1 polymorphisms for association with paediatric asthma. Furthermore, we were interested in whether soluble ICAM1 (sICAM1) serum levels were in correlation with genotypes. The following polymorphisms in ICAM1 were genotyped on 352 children with asthma and 270 controls: rs5491 (resulting in the amino-acid exchange K56M), rs5493 (G241S), rs5498 (K469E), rs5030400 (R478W) and rs885743 in the 3 0 -untranslated region. In addition, sICAM1 serum levels were measured. Only K469E and rs885743 were present in our populations. K469E showed association with asthma (P ¼ 0.0037 with Armitage's trend test). Haplotype analysis by FAMHAP using both polymorphisms revealed association with asthma by Po0.000001. In addition, serum sICAM1 levels were correlated with K469E genotypes (P ¼ 0.009 by Kruskal-Wallis test). We conclude from our data that K469KE is associated with paediatric asthma in the German population. Furthermore, the same polymorphism is correlated with serum levels of sICAM1. Functional analyses have to further clarify the pathophysiological mechanism conferred by the polymorphisms.
Introduction
Intercellular adhesion molecule-1 (ICAM1) is a transmembrane glycoprotein receptor. It belongs to the immunoglobulin superfamily and acts as ligand for b2-integrin molecules present on leucocytes. The gene coding for ICAM1 contains seven exons: exon 1 encodes the signal sequence, exons 2-6 the immunoglobuline (Ig)-like domains 1-5, respectively, and exon 7 the transmembrane region and a short tail of 28 amino acids. 1 The protein is expressed on vascular endothelium, leucocytes, epithelial cells, carcinoma cells, ceratinocytes and astrocytes. Its expression is upregulated by different cytokines, bacterial lipopolysaccharides, oxygen radicals and hypoxia. Elevated levels of ICAM1 are observed in tissues affected by malignancies, inflammatory diseases, artherosclerosis, ischaemia and allogenic organ transplant. 2, 3 Intercellular adhesion molecule-1 mediates leucocyte movement in the tissue, which is referred to as 'leucocyte trafficking': leucocytes rolling along vascular endothelium become firmly linked by binding of b2-integrin receptors to ICAM1. 4 Inhibition of ICAM1 binding to integrin, for example, by antibody treatment diminishes leucocyte transmigration. This observation suggests that binding between ICAM1 and integrins is essential for lymphocyte-mediated immune responses. 5 A soluble form of ICAM1 (sICAM1) is released during the course of inflammatory reactions. 6 Soluble ICAM1 is comprised of the five extracellular Ig-like domains of ICAM1 and is functionally active. It seems likely that sICAM1 modulates inflammation by binding to the leucocyte integrins. 7 The dominant role of ICAM1 in airway inflammation is further supported by the following studies: ICAM1-deficient mice show similar sensitization to ovalbumin, but reduced airway inflammation and airway hyperresponsiveness in comparison to healthy control mice. 8 In addition, ICAM1-deficient mice have an impaired lymphocyte recruitment to the lung and thus less asthmatic symptoms. 9 In humans, ICAM1 expression is elevated in airway biopsies and bronchoalveolar lavage after allergen challenge of patients with allergic asthma. 10 Finally, children were shown to have elevated serum levels of different selectins, including ICAM1, during acute asthma exacerbation. 11 Thus, we were interested in whether a genetic association exists between ICAM1 and bronchial asthma in a German paediatric population. Intercellular adhesion molecule-1 polymorphisms have already been implicated in the susceptibility to other inflammatory diseases like rheumatoid arthritis, 12 inflammatory bowel disease, 13 diabetes mellitus 14 and multiple sclerosis. 15 We chose to study five single-nucleotide polymorphisms (SNPs) in ICAM1: rs5491 (resulting in the amino-acid exchange K56M), rs5493 (G241S), rs5498 (K469E), rs5030400 (R478W) and rs885743 in the 3 0 -untranslated region (UTR). In addition, we measured serum sICAM1 concentrations to investigate whether a correlation exists between the different genotypes and sICAM1 levels.
Materials and methods

Subjects
Asthmatic population. Three hundred and fifty-two children with bronchial asthma (aged 5-18 years) were recruited from the south-western part of Germany between July 2000 and January 2006. The probands were characterized at the University Children's Hospital, Freiburg, Germany, using a standardized clinical protocol. An extended medical history was recorded, including occurrence and duration of wheezing symptoms, previous and acute medications, severity of previous asthma attacks, previous allergic rhinitis or conjunctivitis, atopic dermatitis and any family history of allergic diseases.
The diagnosis was based on a clearcut history of asthmatic symptoms, the use of antiasthmatic medication and the presence of bronchial hyper-reactivity. The antiasthmatic drugs included typical betamimetics like salbutamol and standard corticosteroids used in asthma treatment like budesonide. Bronchial hyper-reactivity was defined as a fall in forced respiratory volume in 1 s by at least 15% in histamine testing or exercise provocation, using standard protocols. 16 The exact recruitment procedure has been described in detail previously. 17 The asthma severity in our population is mild intermittent asthma 6%, mild persistent 83%, moderate persistent 10% and severe persistent 1% of asthmatic children Control population. Two hundred and seventy randomly chosen probands were used as controls (aged 19-40 years). They originate from the same area in the southwestern part of Germany. No medical history was taken and no medical testing was performed on controls.
Genotyping DNA was extracted from peripheral blood leucocytes or buccal smears following standard protocols and column purified (DNA midikit, Qiagen, Germany). Genotyping was performed by restriction fragment length polymorphism (RFLP). The polymorphisms under investigation and the conditions for the RFLP analyses (primer pairs, polymerase chain reaction conditions and restriction enzymes) are given in Table 1 .
Sequencing
For each common polymorphism, three controls (homozygous wild type, heterozygous and homozygous mutation) were sequenced by the dideoxy chain termination method, 18 using the Big Dye Terminator cycle sequencing kit on an ABI 310 sequencer (Applied Biosystems, Darmstadt, Germany). All the following studies included these reference individuals.
In addition, pool sequencing was performed in order to detect the allelic frequency of the polymorphism rs5493. The first pool comprises DNA from 24 asthmatic children, and the second one 27 asthmatic children. Thus, a total of 51 individuals were included.
Statistical analysis of association studies
An association analysis, based on the case-control design, was performed for each SNP using Armitage's trend test. This test takes into account the individuals' genotypes rather than just the alleles, following the guidelines given by Sasieni, 19 as implemented in the program Finetti (Thomas F Wienker, unpublished data; http://ihg.gsf.de/cgi-bin/hw/hwa1.pl and http:// ihg.gsf.de/linkage/download/finetti.zip). The HardyWeinberg equilibrium (HWE) was calculated for each polymorphism in both populations, also using the program Finetti. In addition to analyses based on single polymorphisms, we performed haplotype frequency estimations using FAMHAP. 20 The extent of linkage disequilibrium (LD) between the polymorphisms has been calculated using the Arlequin program.
Measurement of sICAM1 serum concentration
The concentration of sICAM1 in different sera was determined by a commercially available ELISA kit (R&D systems, GmbH, Germany). The following sera were tested: 33 sera of individuals homozygous for the wild-type allele at amino acid 469 (KK), 17 sera of individuals being heterozygous (KE) and 15 sera of individuals being homozygous for the mutation at position 469 (EE). 
Statistical analysis was performed by using the SSPS 11.0 package (SPSS Inc., Chicago, Illinois, USA). The Kruskal-Wallis test was used to determine association between levels of sICAM1 and the amino-acid variant K479E.
Approval
The collection of blood and serum and the experimental procedures were approved by the Ethical Committee of the University of Freiburg. A statement of informed consent was signed by all participants, or in the case of children, signed by their parents.
Results
Genotyping
The two common polymorphisms -rs5498 (i.e. K469E) and rs885743 in the 3 0 -UTR -were typed on 352 children with bronchial asthma and 270 controls. The position of the polymorphisms and the genotype distribution in both populations are listed in Table 2 . All polymorphisms were in HWE (data not shown).
The previously described polymorphisms, rs5491, rs5493 and rs5030400, were not found in 100 children and thus not investigated further. To further ensure that the polymorphism rs5493 does not occur in our asthmatic population, we performed pool sequencing using DNA from 51 asthmatic children in two DNA pools. In both pools, only the wild-type base peak was detectable.
Association analysis
The P-values for association are also listed in Table 2 . Association was observed between bronchial asthma and K469E (P ¼ 0.0037) In contrast, rs885743 in the 3 0 -UTR showed no association with the disease.
Linkage disequilibrium and haplotype analyses Both polymorphisms were in strong LD to each other as calculated by Arlequin (P ¼ 0.0000). The haplotypes occurring in the populations are listed in Table 3 . All four possible haplotypes exist in our populations.
Haplotypes bearing one wild-type allele and one mutant allele (i.e. haplotypes 12 and 21) were more frequent in the asthmatic population than in controls (0.12 and 0.09 in asthmatics vs 0.034 or 0.047 in controls, respectively). In contrast, the haplotype bearing both mutant alleles (i.e. 22) was more frequent in controls than in asthmatics (0.37 vs 0.25).
The haplotypes were associated with asthma with a P-value of o0.000001 as calculated by FAMHAP.
Serum levels of sICAM1 and association with K469E
Owing to the strong association of K469E with asthma in our population, we were interested in whether K469E influences sICAM1 serum levels. sICAM1 levels were measured in three groups of sera: homozygous for K at position 469, heterozygous K/E and homozygous for E. The results are shown in Figure 1 . By using the KruskalWallis test, a significant difference was observed between the groups (P ¼ 0.009).
Discussion
Asthma is characterized by airway hyper-responsiveness and inflammation of the lung, accompanied by the accumulation of lymphocytes and eosinophils. The ICAM1 in the genetics of childhood asthma B Puthothu et al emigration of lymphocytes from the bloodstream is mediated by different adhesion molecules. In the present study, we concentrated on the relationship between polymorphisms within the adhesion molecule ICAM1 and asthma. As mentioned above, ICAM1 has already been investigated in the context of allergic diseases in mice as well as in man. In addition, one genetic association study has been conducted so far: Li et al.
21
reported that the two amino-acid variants 241S and 469E within ICAM1 indicate haplotypes, which are associated with a reduced risk of asthma.
In our asthmatic population, the 241S variant was not detectable, neither by RFLP nor by sequencing. However, we found association of K469E with paediatric asthma (P ¼ 0.0037). 469E was under-represented in asthmatic children in comparison to controls. Thus, 469E might confer protection against the development of asthma. This result is in accordance with the above-mentioned association study. 21 The amino-acid exchange from glutamic acid (negative polar) to lysin (positive polar) is located in the fifth Ig-like domain of ICAM1. This region seems to be particularly important for the dimerization of ICAM1. Intercellular adhesion molecule-1 dimers exhibit -in comparison to monomers -an enhanced binding to lymphocyte function-associated protein-1. 22, 23 Therefore, one might speculate that the amino-acid exchange diminishes ICAM1 dimerization and in turn leads to a decreased integrin receptor binding. Consecutively, less leucocytes migrate to the side of inflammation, and the inflammatory response is attenuated.
We have also chosen to study one polymorphism in the 3 0 -UTR of ICAM1. The polymorphism rs885743 represents a so-called tag SNP and was selected on the basis of the International Hapmap Project (www.hapmap.org). A tag SNP is in high LD with other additional polymorphisms. By genotyping a tag SNP, these polymorphisms are also covered and thus genotyping can be largely simplified. The polymorphism rs885743 per se was not in association with asthma in our populations. Thus, it seems unlikely that this polymorphism or the polymorphisms in LD with this tag SNP have a functional impact on disease progression. However, haplotype analyses including rs885743 and K469E revealed very strong association with asthma (Po0.000001). This further supports the involvement of ICAM1 in the genetic predisposition to asthma.
It is not possible to decide on the basis of our results which polymorphism in ICAM1 is the most important one in the development of asthma. Most likely, it is K469E, as it is an amino-acid exchange and association of this polymorphism was repetitively found with other disease as well. However, it still remains possible that another SNP in tight LD is the real disease-causing polymorphism. In addition, there is nothing known about a possible interaction between both SNPs so far. rs885743 is a non-coding SNP and thus may alter gene expression or RNA stability, whereas K469E alters the protein structure and accordingly may effect protein function. Thus, a direct interaction between both polymorphisms seems unlikely.
On the basis of the strong association of K469E with asthma, we were interested in whether a correlation exists between the concentration of sICAM1 in serum and K469E genotypes. Serum samples of children homozygous for K469 showed a mean concentration of 270.2 ng/ml sICAM1, whereas 322.6 and 321 ng/ml sICAM1 were measured in serum of heterozygous children and children homozygous for 469E, respectively. Serum sICAM1 levels have been reported to be less than 500 ng/ml in normal controls. 24 Thus, all sera tested in our study had an sICAM1 level within the normal range. This might not be surprising as all samples were taken from children without present symptoms of asthma.
Statistical analyses by the Kruskal-Wallis test showed that children with the K489 genotype had significant lower sICAM1 levels than heterozygous children and children homozygous for 469E (P ¼ 0.009). Thus taken together, children bearing the 469KK genotype are more likely to have asthma, but at the same time have lower sICAM1 levels. At the first sight, this might be confusing, as it has been demonstrated that during acute asthma exacerbation sICAM1 levels are elevated in children. 11 But again, one should bear in mind that our samples were not taken during acute asthma attacks, but in times of no asthmatic symptoms. Soluble ICAM1 levels measured by us should therefore rather present the levels determined by the genetic background than by the disease. Furthermore, several studies suggest that sICAM1 indeed protects against inflammation. sICAM1 is formed by proteolytic cleavage of ICAM1. By binding to integrins, it ameliorates the interaction of ICAM1 with these molecules and thus diminishes leucocyte trafficking. 25, 26 Thus, we propose that children bearing the 469K genotype primarily have lower sICAM1 levels than controls and are therefore more prone to develop inflammatory diseases like asthma. Once the disease process is initiated, sICAM1 levels raise and exceed normal levels.
We only tested K469E for association with sICAM1 levels because -as already mentioned above -this polymorphism is most likely more important than rs885743. The best approach to further clarify the impact of both polymorphisms on sICAM1 levels would be to test directly the different haplotypes for association with sICAM1 levels. Unfortunately, the case numbers are too small for such analyses and no more sera of patients were available for our study.
Furthermore, the results of serum sICAM1 levels might suggest a dominant effect of K469E. This dominant effect was not seen in the predisposition to asthma (data not shown). This could be owing to a different impact of the polymorphisms on sICAM1 levels and protein function as already discussed above. However, this still remains speculation.
Two other studies have already investigated a possible association of ICAM1 polymorphisms with sICAM1 levels. The first described correlation between K29M (identical to K57M in our study) and sICAM1 levels. 27 The second found association of G241S with sICAM1. 28 In our populations, both polymorphisms were absent, so we were not able to replicate these findings.
We conclude from our data that the amino-acid variant K469KE is associated with paediatric asthma in the German population. Furthermore, the same polymorphism is correlated with lower serum levels of soluble ICAM1. Further studies are needed to confirm the results. In particular, functional analyses have to clarify ICAM1 in the genetics of childhood asthma B Puthothu et al the pathophysiological mechanism conferred by this polymorphism.
